Parasite Clearance and Protection from Plasmodium Falciparum Infection (PCPI): a Three-arm, Parallel, Double-blinded, Placebo-controlled, Randomised Trial of Presumptive Sulfadoxine-pyrimethamine Versus Sulfadoxine-pyrimethamine Plus Amodiaquine...

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Sep 26

PMID 39327613

Authors

Rosario Martinez-Vega

Wilfred Fon Mbacham

Innocent Ali

Akindeh Nji

Andria Mousa

Khalid B Beshir

Ana Chopo-Pizarro

Harparkash Kaur

Lucy Okell

Helle Hansson

Emma Filtenborg Hocke

Michael Alifrangis

Roland Gosling

Cally Roper

Colin Sutherland

R Matthew Chico

Affiliations

Soon will be listed here.

Abstract

Background: The World Health Organization 2022 malaria chemoprevention guidelines recommend providing a full course of antimalarial treatment at pre-defined intervals, regardless of malaria status to prevent illness among children resident in moderate to high perennial malaria transmission settings as perennial malaria chemoprevention (PMC) with sulfadoxine-pyrimethamine (SP). The dhps I431V mutation circulating in West Africa has unknown effect on SP protective efficacy.

Methods: This protocol is for a three-arm, parallel, double-blinded, placebo-controlled, randomised trial in Cameroon among children randomly assigned to one of three directly-observed treatment groups: (i) Group 1 (n = 450) receives daily artesunate (AS) placebo on days - 7 to -1, then active SP plus placebo amodiaquine (AQ) on day 0, and placebo AQ on days 1 and 2; (ii) Group 2 (n = 250) receives placebo AS on days - 7 to -1, then active SP and AQ on day 0, and active AQ on days 1 and 2; and (iii) Group 3 (n = 200) receives active AS on days - 7 to -1, then placebo SP on day 0 and placebo AQ on days 0 to 2. On days 0, 2, 5, 7, and thereafter weekly until day 28, children provide blood for thick smear slides. Dried blood spots are collected on the same days and weekly from day 28 to day 63 for quantitative polymerase chain reaction (qPCR) and genotype analyses.

Discussion: Our aim is to quantify the chemopreventive efficacy of SP, and SP plus AQ, and measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP chemoprevention. We will report unblinded results including: (i) time-to-parasite clearance among SP and SP plus AQ recipients who were positive on day 0 by qPCR and followed to day 63; (ii) mean duration of SP and SP plus AQ protection against infection, and (iii) mean duration of symptom-free status among SP and SP plus AQ recipients who were parasite free on day 0 by qPCR. Our study is designed to compare the 28-day follow-up of the new WHO malaria chemoprevention efficacy study protocol with extended follow-up to day 63.

Trial Registration: ClinicalTrials.gov NCT06173206; 15/12/2023.

References

Amimo F, Lambert B, Magit A, Sacarlal J, Hashizume M, Shibuya K . resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends. BMJ Glob Health. 2020; 5(11). PMC: 7678238. DOI: 10.1136/bmjgh-2020-003217. View

Mousa A, Cuomo-Dannenburg G, Thompson H, Chico R, Beshir K, Sutherland C . Measuring protective efficacy and quantifying the impact of drug resistance: A novel malaria chemoprevention trial design and methodology. PLoS Med. 2024; 21(5):e1004376. PMC: 11081503. DOI: 10.1371/journal.pmed.1004376. View

. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet. 2020; 396(10265):1829-1840. PMC: 7718580. DOI: 10.1016/S0140-6736(20)32227-3. View

Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N . Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ. 2005; 331(7519):727-33. PMC: 1239974. DOI: 10.1136/bmj.331.7519.727. View

Grobusch M, Lell B, Schwarz N, Gabor J, Dornemann J, Potschke M . Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007; 196(11):1595-602. DOI: 10.1086/522160. View

Macete E, Aide P, Aponte J, Sanz S, Mandomando I, Espasa M . Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis. 2006; 194(3):276-85. DOI: 10.1086/505431. View

Zani B, Gathu M, Donegan S, Olliaro P, Sinclair D . Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014; (1):CD010927. PMC: 4470355. DOI: 10.1002/14651858.CD010927. View

Nag S, Dalgaard M, Kofoed P, Ursing J, Crespo M, Andersen L . High throughput resistance profiling of Plasmodium falciparum infections based on custom dual indexing and Illumina next generation sequencing-technology. Sci Rep. 2017; 7(1):2398. PMC: 5445084. DOI: 10.1038/s41598-017-02724-x. View

Esu E, Oringanje C, Meremikwu M . Intermittent preventive treatment for malaria in infants. Cochrane Database Syst Rev. 2021; 7:CD011525. PMC: 8406727. DOI: 10.1002/14651858.CD011525.pub3. View

10.

Adegbola A, Ijarotimi O, Ubom A, Adesoji B, Babalola O, Hocke E . A snapshot of the prevalence of dihydropteroate synthase-431V mutation and other sulfadoxine-pyrimethamine resistance markers in Plasmodium falciparum isolates in Nigeria. Malar J. 2023; 22(1):71. PMC: 9976540. DOI: 10.1186/s12936-023-04487-5. View

11.

Griffin J, Hollingsworth T, Okell L, Churcher T, White M, Hinsley W . Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med. 2010; 7(8). PMC: 2919425. DOI: 10.1371/journal.pmed.1000324. View

12.

Swysen C, Vekemans J, Bruls M, Oyakhirome S, Drakeley C, Kremsner P . Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malar J. 2011; 10:223. PMC: 3220650. DOI: 10.1186/1475-2875-10-223. View

13.

Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K . Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. Lancet Infect Dis. 2022; 23(3):361-370. DOI: 10.1016/S1473-3099(22)00593-X. View

14.

Sutherland C, Fifer H, Pearce R, Bin Reza F, Nicholas M, Haustein T . Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom. Antimicrob Agents Chemother. 2009; 53(8):3405-10. PMC: 2715629. DOI: 10.1128/AAC.00024-09. View

15.

Waltmann A, Rogawski McQuade E, Chinkhumba J, Operario D, Mzembe E, Itoh M . The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens. EBioMedicine. 2022; 77:103871. PMC: 8866062. DOI: 10.1016/j.ebiom.2022.103871. View

16.

Plowe C . Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar J. 2022; 21(1):104. PMC: 8943514. DOI: 10.1186/s12936-022-04115-8. View

17.

Griffin J, Ferguson N, Ghani A . Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun. 2014; 5:3136. PMC: 3923296. DOI: 10.1038/ncomms4136. View

18.

Oguike M, Falade C, Shu E, Enato I, Watila I, Baba E . Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum in Nigeria and the regional emergence of dhps 431V. Int J Parasitol Drugs Drug Resist. 2016; 6(3):220-229. PMC: 5094156. DOI: 10.1016/j.ijpddr.2016.08.004. View

19.

Kimura I, Miyamoto J, Ohue-Kitano R, Watanabe K, Yamada T, Onuki M . Maternal gut microbiota in pregnancy influences offspring metabolic phenotype in mice. Science. 2020; 367(6481). DOI: 10.1126/science.aaw8429. View

20.

Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M . Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001; 357(9267):1471-7. DOI: 10.1016/S0140-6736(00)04643-2. View